Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study.

Publication ,  Journal Article
Dangas, G; Baber, U; Sharma, S; Giustino, G; Sartori, S; Nicolas, J; Goel, R; Mehta, S; Cohen, D; Angiolillo, DJ; Zhang, Z; Camaj, A; Cao, D ...
Published in: EuroIntervention
March 18, 2022

BACKGROUND: In the TWILIGHT trial, ticagrelor monotherapy after a short course of dual antiplatelet therapy (DAPT) was shown to be a safe bleeding avoidance strategy in high-risk patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES). AIMS: The aim of this study was to evaluate the effects of ticagrelor monotherapy after three-month DAPT in patients undergoing PCI, according to DES type. METHODS: In the current sub-analysis from TWILIGHT, patients were stratified into three groups based on DES type: durable polymer everolimus-eluting stents (DP-EES), durable polymer zotarolimus-eluting stents (DP-ZES), and biodegradable polymer DES (BP-DES). Bleeding and ischaemic outcomes were assessed at one year after randomisation. RESULTS: Out of 5,769 patients, 3,014 (52.2%) had DP-EES, 1,350 (23.4%) had DP-ZES and 1,405 (24.4%) had BP-DES. Compared with ticagrelor plus aspirin, ticagrelor monotherapy had significantly lower BARC type 2, 3 or 5 bleeding compared with DAPT; DP-EES (3.8% vs 6.7%; HR 0.56, 95% CI: 0.41-0.78), DP-ZES (4.6% vs 6.9%; HR 0.66, 95% CI: 0.42-1.04) and BP-DES (4.2% vs 7.9%; HR 0.52, 95% CI: 0.33-0.81; pinteraction=0.76). Ticagrelor monotherapy resulted in similar rates of death, MI, or stroke: DP-EES (4.2% vs 4.3%; HR 0.97; 95% CI: 0.68-1.37); DP-ZES (4.1% vs 3.1%; HR 1.32; 95% CI: 0.75-2.33); BP-DES (3.9% vs 4.2%; HR 0.92; 95% CI: 0.54-1.55; pinteraction=0.60). In both unadjusted and covariate-adjusted analyses, DES type was not associated with any differences in ischaemic or bleeding complications. CONCLUSIONS: As compared with ticagrelor plus aspirin, ticagrelor monotherapy after a short DAPT duration lowered bleeding complications without increasing the ischaemic risk, irrespective of DES type. We observed no significant differences among DES types.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

EuroIntervention

DOI

EISSN

1969-6213

Publication Date

March 18, 2022

Volume

17

Issue

16

Start / End Page

1330 / 1339

Location

France

Related Subject Headings

  • Treatment Outcome
  • Ticagrelor
  • Stents
  • Platelet Aggregation Inhibitors
  • Percutaneous Coronary Intervention
  • Humans
  • Everolimus
  • Drug-Eluting Stents
  • 3201 Cardiovascular medicine and haematology
  • 0104 Statistics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dangas, G., Baber, U., Sharma, S., Giustino, G., Sartori, S., Nicolas, J., … Mehran, R. (2022). Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. EuroIntervention, 17(16), 1330–1339. https://doi.org/10.4244/EIJ-D-21-00721
Dangas, George, Usman Baber, Samin Sharma, Gennaro Giustino, Samantha Sartori, Johny Nicolas, Ridhima Goel, et al. “Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study.EuroIntervention 17, no. 16 (March 18, 2022): 1330–39. https://doi.org/10.4244/EIJ-D-21-00721.
Dangas G, Baber U, Sharma S, Giustino G, Sartori S, Nicolas J, et al. Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. EuroIntervention. 2022 Mar 18;17(16):1330–9.
Dangas, George, et al. “Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study.EuroIntervention, vol. 17, no. 16, Mar. 2022, pp. 1330–39. Pubmed, doi:10.4244/EIJ-D-21-00721.
Dangas G, Baber U, Sharma S, Giustino G, Sartori S, Nicolas J, Goel R, Mehta S, Cohen D, Angiolillo DJ, Zhang Z, Camaj A, Cao D, Briguori C, Dudek D, Escaned J, Huber K, Collier T, Kornowski R, Kunadian V, Moliterno DJ, Ohman EM, Weisz G, Gil R, Krucoff MW, Kaul U, Oldroyd KG, Sardella G, Shlofmitz R, Witzenbichler B, Kastrati A, Han Y-L, Steg PG, Pocock S, Gibson CM, Mehran R. Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. EuroIntervention. 2022 Mar 18;17(16):1330–1339.

Published In

EuroIntervention

DOI

EISSN

1969-6213

Publication Date

March 18, 2022

Volume

17

Issue

16

Start / End Page

1330 / 1339

Location

France

Related Subject Headings

  • Treatment Outcome
  • Ticagrelor
  • Stents
  • Platelet Aggregation Inhibitors
  • Percutaneous Coronary Intervention
  • Humans
  • Everolimus
  • Drug-Eluting Stents
  • 3201 Cardiovascular medicine and haematology
  • 0104 Statistics